Navigation Links
Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing

TEL-AVIV, Israel, Nov. 29 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd. (TASE, Nasdaq: EMITF) ("EI" or the "Company") announced that on November 28, 2007, InSightec Ltd. ("InSightec"), a subsidiary of the Company reported that it has signed and consummated an agreement for an internal round of financing in the aggregate amount of $30 million from its existing investors, namely: Elbit Ultrasound (Netherlands) B.V., a fully owned subsidiary of the Company ("EUN"); GE Capital Equity Holdings Inc., a subsidiary of General Electric Company (NYSE: GE); MediTech Advisors LLC ("MTA"), a Delaware private limited liability company specializing in the healthcare marketplace; and certain directors and officers of InSightec.

The investment is in the form of allotment and purchase of Series A Preferred convertible shares of InSightec, which are convertible to InSightec's ordinary shares subject to the fulfillment of certain conditions stipulated in the agreement. EUN's share in this round of investment totals $19,829,643. The investors have been granted certain preferential rights attached to the Series A Preferred Shares of InSightec under the articles of association of InSightec, as amended, and certain additional rights under a securityholders agreement that was executed by and among InSightec and the major investors, as stipulated in the said agreement.

Following the completion of this latest round of investment, the fully diluted ownership of EUN and Elbit Ultrasound Ltd. in InSightec will be approximately 53%.

InSightec reported that the proceeds of the investment would be applied to expand its research and development efforts, for marketing and sales activities, and for general corporate purposes.

Mr. Shimon Yitzhaki, President of the Company, said, "Following InSightec's receipt of the European CE approval for pain palliation of bone metastases based on clinical results demonstrating that this technology has the potential to become an important treatment alternative for this patient population, and the receipt of the FDA IDE approval for starting a phase III clinical trial in the US for the treatment of bone metastases, InSightec has decided to increase and accelerate its R&D efforts towards the simultaneous development of the InSightec's technologies which are necessary for the expansion into new oncology areas such as: bone metastases, prostate cancer, breast cancer, liver tumors and brain tumors, in order to receive FDA approvals for those applications and treatments within a shorter period. Meeting this task shall enable InSightec to speed up the bringing of its products into the market for the benefit of the potential patients and the cancer defeat straggle."

About Elbit Imaging Ltd.

Elbit Imaging Ltd. ("EI") is a subsidiary of Europe Israel (M.M.S.) Ltd. EI's activities are divided into the following principal fields: (i) Initiation, construction, operation, management and sale of shopping and entertainment centers in Israel, Central and Eastern Europe and India; (ii) Hotels ownership, primarily in major European cities, as well as operation, management and sale of same through its subsidiary, Elscint Ltd.; (iii) Investments in the research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, through its subsidiary, InSightec Ltd.; and (iv) Other activities consisting of the distribution and marketing of women's fashion and accessories through our wholly-owned Israeli subsidiary, Elbit Trade & Retail Ltd., and venture-capital investments.

About InSightec

InSightec Ltd. is a privately held company owned by EI's wholly owned subsidiaries EUN and Elbit Ultrasound Ltd., General Electric, MediTech Advisors, LLC and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 150 employees and has invested more than $100 million in research, development, and clinical investigations. Its U.S. headquarter is located in Dallas, Texas. For more information, please go to:

About ExAblate

The ExAblate(R) is the first system to use the breakthrough MRgFUS technology that combines MRI -- to visualize tissues in the body, plan the treatment and monitor treatment outcome in real time -- and high intensity focused ultrasound to thermally ablate tumors inside the body non-invasively. MR thermometry, provided uniquely by the system, allows the physician to control and adjust the treatment in real time to ensure that the targeted tumor is fully treated and surrounding tissue is spared. ExAblate received FDA approval for the treatment of symptomatic uterine fibroids in October 2004. ExAblate has been recognized for its innovation and potential to serve mankind and has been awarded the 2004 European Union's Information Society Technologies grand prize, The Wall Street Journal's 2004 Technology Innovation Awards, Advanced Imaging's 2005 Solutions of the Year, the Red Herring 100 Europe 2007 Award and World Economic Forum Technology Pioneers for 2008.

Any forward looking statements with respect to EI's business, financial condition and results of operations included in this release are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward looking statements, including, but not limited to, ability to find suitable locations, receipt of approvals and permits for zoning and construction, delays in construction, dependency on partners in the hotels business, competition, risks relating to operations in Eastern Europe and Asia (including India) and risks relating to our image guided treatment, economic conditions, as well as certain other risk factors which are detailed from time to time in EI's filings with the Securities and Exchange Commission including, without limitation, Annual Report on Form 20-F for the fiscal year ended December 31, 2006, filed with the Securities and Exchange Commission on July 3, 2007.

For Further Information:

Company Contact Investor Contact

Shimon Yitzhaki, President Leslie Wolf-Creutzfeldt

Elbit Imaging Ltd. The Global Consulting Group

(972-3) 608-6000 1-646-284-9472

Dudi Machluf, CFO

Elbit Imaging Ltd.

(972-3) 608-6024

SOURCE Elbit Imaging Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Elbit Medical Imaging Ltd. Announces Publication of a Prospectus in Israel
2. Elbit Medical Imaging Ltd. Announces Adjournment of its Annual General Meeting
3. Brain imaging reveals breakdown of normal emotional processing
4. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
5. Fry Construction Selected for High-Profile Medical Imaging Project
6. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
7. Imaging Software Helps Track, Treat Injured Brains
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
10. Revision: Ziehm Imaging and BrainLAB Announce Partnership for Intra-Operative 3D Imaging and Computer Assisted Surgery (CAS)
11. Brain Imaging Expert Recruited to Study Autism at The Childrens Hospital of Philadelphia
Post Your Comments:
(Date:12/1/2015)... D.C. (PRWEB) , ... December 01, 2015 , ... ... updated, comprehensive website detailing the important role that meat and poultry play ... in meat and poultry, a nutrition quiz where visitors can check their “meat ...
(Date:12/1/2015)... ... December 01, 2015 , ... Integrated Rental Services (“Integrated ... Industries International, LLC (“JII”). , With support from JII, Integrated Rental is poised ... hospitals, surgery centers, clinics, research labs and medical facilities across the United States. ...
(Date:12/1/2015)... ... 01, 2015 , ... Califia Farms , one of the fastest growing ... won top honors in Beverage World Magazine’s Global Packaging Design Awards, taking home the ... been selected as a 2015 U.S.A. Taste Champion in the American Masters of Taste ...
(Date:12/1/2015)... ... December 01, 2015 , ... December ... seen vast improvements in scientific research and discoveries, leading us to better understand ... and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of ... is the focus of numerous abstracts accepted for presentation here, at the 101st ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... N.J. , Dec. 1, 2015 ... held in San Francisco, CA ... solutions to the coronary marketplace. During a satellite ... in Stent Design to Minimize Restenosis", a renowned ... currently available Medinol NIRxcell™ CoCr Coronary Stent System ...
(Date:12/1/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... announced today that the company will present at the LD ... at the Luxe Sunset Boulevard Hotel in Los ... Relmada Therapeutics, will present on Thursday, December 3, at 9:00 ... . Please register at least 10 minutes prior to the ...
(Date:12/1/2015)...  InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company ... cardiovascular conditions via the inhalation route, today announced that ... Australia . InCarda is planning to undertake its ... in the first half of 2016. The company ... Adelaide and Melbourne.  In addition, ...
Breaking Medicine Technology: